Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action Mint add-on to PPI for inadequately controlled GORD
2012-004470-25Phase 3Completed
- Sponsor
- Reckitt
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Gaviscon Double Action Mint add-on with Matched placebo liquid add-on (2 arms). Started Nov 2012; status: completed.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2012-004470-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004470-25.